2018 Volume 64 Issue Suppl.1 Pages 179-184
Objective: Our facility has previously reported that periodic exercise, especially brisk walking with a monthly distance of approximately 120 km, is healthy in men. In the present study, we examined the relationship between cancer-related mortality and prostate-specific antigen (PSA) values in prostate cancer patients by providing guidance concerning brisk walking, especially walking for a distance of 120 km.
Materials and Methods: After diagnosis of prostate cancer, patients who were not indicated for operative treatment of the prostate cancer and selected combined androgen blockade (CAB) therapy also received guidance concerning brisk walking once monthly.
We examined the outdoor one-month walking distance of each patient once annually by pedometer. Exercise quantity, mortality rate, and serum PSA values were examined over an eight-year period.
Results: CAB therapy was initially initiated in 102 prostate cancer patients. Of the 48 persons who died during 8 years, mortality due to prostate cancer occurred in 41.6% (20 persons). There were significantly fewer prostate cancer-related deaths in the patient group that performed monthly exercise for 120 km or more than in the patient group that walked less than 120 km.
Conclusions: The results of the present study demonstrate the possibility that exercise may lead to inhibition of prostate cancer and inhibition of PSA re-elevation. Actively introducing exercise into medical treatment may be effective for treating prostate cancer.
